Lv42
470 积分 2020-07-12 加入
The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab
16小时前
待确认
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
16小时前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
19小时前
已完结
The present and future of bispecific antibodies for cancer therapy
23天前
已完结
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
1个月前
已完结
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial
8个月前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
8个月前
已完结
Digital image analysis improves precision of PD‐L1 scoring in cutaneous melanoma
11个月前
已完结
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
1年前
已完结
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
1年前
已完结
皖公网安备34019202002308
